Core Viewpoint - Molina Healthcare, Inc. (NYSE:MOH) is currently facing a resistance level around $170.50, which is expected to change in January as the stock is unlikely to remain at this level for long [1][2]. Group 1: Resistance and Support Levels - The stock previously found support at $170.50 in September, leading to a rally, but this support was broken in October, resulting in a decline in share price [4]. - When the stock price rallied back to the resistance level in December, many investors who had previously bought at support placed sell orders, creating a concentration of resistance at the same price [5]. Group 2: Potential Outcomes - There is a possibility that buyers may eventually overpower sellers, leading to a breakout above the resistance level, which typically results in an upward trend as buyers compete to outbid each other [6]. - Conversely, if sellers become anxious and lower their selling prices, it could trigger a downward movement, creating a snowball effect as more sellers follow suit [7].

Key Points VCSH costs slightly less and offers a marginally higher dividend yield than IGSB IGSB holds thousands more bonds than VCSH, and has a much lower beta. Both ETFs have nearly identical five-year drawdowns and similar recent total returns These 10 stocks could mint the next wave of millionaires › The Vanguard Short-Term Corporate Bond ETF (VCSH) and the iShares 1-5 Year Investment Grade Corporate Bond ETF (IGSB) differ most in portfolio breadth, sector tilts, and volatility, with VCSH off ...

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE: ARDT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Ardent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On November 12, ...

Core Insights - Modivcare Inc. has successfully completed its financial restructuring and emerged from Chapter 11 protection, significantly reducing its funded debt by $1.1 billion, which is over 85% of its previous debt, and adding $100 million in new capital [2][3] Financial Restructuring - The company has reduced its annual cash interest expense and is emerging with a stronger balance sheet, improved liquidity, and increased financial flexibility [2] - Modivcare continued to operate normally during the restructuring process, ensuring no interruption to services for clients, members, providers, or partners [2] Leadership and Strategy - The CEO of Modivcare stated that the company is now positioned to focus on delivering reliable access to care and investing in necessary capabilities for the future [3] - Modivcare emerges as a privately-owned company under a group of seasoned investors committed to its success [3][4] Future Outlook - The restructuring is expected to enhance Modivcare's ability to invest in technology, data, and operational capabilities that are crucial for clients [4] - New directors with significant financial and strategic investments will help shape the company's future alongside experienced Board members [4] Company Overview - Modivcare is a technology-enabled healthcare services company providing integrated supportive care solutions, addressing social determinants of health by connecting members to essential care services [8] - The company offers non-emergency medical transportation, personal care services, and remote patient monitoring solutions [8]

Core Viewpoint - The article highlights the positive perceptions of China's healthcare system from foreign vloggers, showcasing its efficiency, accessibility, and affordability compared to Western systems [1][2][5][10]. Group 1: Foreign Perspectives on Chinese Healthcare - An American vlogger praised the efficiency of China's healthcare system, noting clear procedures and minimal waiting times [1][2]. - A British vlogger shared experiences in Shanghai, emphasizing the contrast between Chinese and Western healthcare systems, which sparked discussions on social media [3]. - An Italian vlogger also reported high efficiency in smaller Chinese cities, indicating a broader positive sentiment among foreign visitors [4]. Group 2: Improvements in Healthcare Accessibility - Personal accounts illustrate that China's healthcare system has become more balanced and accessible, benefiting ordinary citizens [5][15]. - Grassroots medical institutions accounted for over 50% of total outpatient visits during the 14th Five-Year Plan, highlighting local accessibility [15]. - Technological advancements and integrated medical alliances have improved service capacity and accessibility in rural areas [16][17][18]. Group 3: Healthcare Costs and Insurance - The American vlogger noted that he paid only $4 for registration in China, contrasting sharply with the $300 cost in the US [11]. - A comprehensive health check in China cost 253 yuan ($36), with results delivered within 24 hours, showcasing affordability and efficiency [12]. - The national basic medical insurance coverage rate remained stable at around 95% during the 14th Five-Year Plan, supporting the healthcare system's accessibility [24]. Group 4: Future Developments and Initiatives - The Recommendations for the 15th Five-Year Plan emphasize public wellbeing and the Healthy China Initiative as core priorities [7][25]. - Several provinces have begun to implement localized plans that align with the Healthy China strategy, indicating ongoing development in healthcare [25]. - The article concludes with a vlogger's initiative to create a service for overseas visitors to navigate China's healthcare system, reflecting a growing interest in its advancements [26].

Core Insights - Women We Admire has announced The Top 50 Women Leaders in Human Resources for 2025, highlighting the significant role of HR leaders in shaping workforce policies and practices across various industries [1] Group 1: Honorees and Their Contributions - Ola Snow, Chief Human Resources Officer at Cardinal Health, oversees multiple functions including human resources and diversity initiatives, focusing on workforce strength and employee growth [2] - Sandy McIntosh, Executive Vice President of People & Culture at TELUS, serves as a trusted advisor to leadership, leading strategies that enhance business and culture practices for better human outcomes [3] - Sherry Kenyon, Human Resources Business Partner at BASF, has over 25 years of experience in balancing company objectives with employee engagement, playing a key role in transitioning to new electronic processes [4] Group 2: Recognition and Impact - The announcement serves to celebrate the accomplishments of women leaders in HR, emphasizing their influence on organizational operations and employee experiences [5] - The full list of honorees includes notable figures from various companies, showcasing a diverse range of leadership in human resources [6]

Core Viewpoint - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Ardent Health, Inc., focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1][2]. Company Overview - Ardent Health, Inc. is a healthcare provider operating in growing midsize urban communities across the United States [2]. - The company raised $192 million in its initial public offering on July 18, 2024, selling 12 million shares at $16 per share [2]. Recent Developments - On November 12, 2025, Ardent Health announced its third quarter 2025 earnings, which missed consensus estimates primarily due to pronounced payor denials and a $54 million adjustment related to adverse prior period claim developments from 2019 to 2022 [3]. - The CFO, Alfred Lumsdaine, indicated that a "change in accounting estimate" led to the earlier recognition of reserves, resulting in a revenue reduction of $43 million for the quarter [3].

Core Viewpoint - Investors are currently rebalancing portfolios and strategizing for the upcoming year, with a focus on underperforming stocks, particularly UnitedHealth Group Inc, which has faced significant challenges in 2025 [1]. Group 1: Company Performance - UnitedHealth Group Inc (NYSE:UNH) is the worst performer on the Dow in 2025, primarily due to controversies following the murder of CEO Brian Thompson and a surprise earnings miss in April, leading to a lowered full-year outlook [2]. - The stock has seen a significant decline, losing more than 35% this year, with its price dropping to $324.13, marking its lowest level since April 2020 [3]. - The stock is on track to close out 2025 with only five monthly wins, indicating a prolonged period of underperformance [3]. Group 2: Market Sentiment and Volatility - Despite the underperformance, short-term options traders are leaning bullish, as indicated by a low Schaeffer's put/call open interest ratio, which ranks higher than only 4% of annual readings [5]. - The Schaeffer's Volatility Index (SVI) for UnitedHealth is at 30%, in the 19th percentile of its annual range, suggesting that near-term option traders are expecting low volatility [6]. - Historically, UnitedHealth has outperformed volatility expectations, as reflected in its Schaeffer's Volatility Scorecard (SVS) of 99 out of 100 [6].

Core Insights - HCA Healthcare, Inc. is a significant player in the healthcare services sector with a market capitalization of $107.7 billion and is set to announce its fiscal Q4 earnings for 2025 soon [1] Financial Performance - Analysts anticipate HCA to report a profit of $7.37 per share for the upcoming quarter, reflecting an 18.5% increase from $6.22 per share in the same quarter last year [2] - For the current fiscal year ending in December, HCA is expected to achieve a profit of $27.60 per share, which is a 25.7% increase from $21.96 per share in fiscal 2024, with further growth projected to $29.66 per share in fiscal 2026 [3] Stock Performance - HCA's shares have increased by 55.5% over the past 52 weeks, significantly outperforming the S&P 500 Index's 16% return and the State Street Health Care Select Sector SPDR ETF's 12.5% increase during the same period [4] Recent Developments - Following a better-than-expected Q3 earnings release, HCA's shares rose by 1.6%. The company reported total revenue of $19.2 billion, a 9.6% year-over-year increase, exceeding consensus expectations by 3.6%. Adjusted EPS improved by 42% from the previous year to $6.96, surpassing analyst estimates of $5.65 [5] - HCA has raised its fiscal 2025 guidance, now expecting revenue between $75 billion and $76.5 billion, and EPS between $27 and $28 [5] Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for HCA, with 14 out of 25 analysts recommending "Strong Buy," one suggesting "Moderate Buy," nine indicating "Hold," and one advising "Strong Sell." The mean price target for HCA is $486.41, suggesting a 3% potential upside from current levels [6]

Core Insights - Elevance Health, Inc. is valued at approximately $76.5 billion and aims to improve health outcomes for individuals, families, and communities throughout their healthcare journey [1] - The company serves over 109 million consumers with a comprehensive portfolio that includes medical, pharmacy, behavioral, clinical, home health, and complex care solutions [2] Financial Performance - Elevance Health's total revenue for fiscal 2025 third-quarter increased by 12% year over year to $50.71 billion, surpassing consensus estimates of $49.52 billion [5] - Despite a 30% year-over-year decline in adjusted EPS to $6.03, this figure exceeded expectations of $4.98, indicating strong operational execution [6] Market Expectations - Wall Street analysts predict a nearly 17% year-over-year decline in EPS to $3.19 for the upcoming fiscal 2025 fourth-quarter earnings report [3] - Projections indicate continued pressure on earnings, with fiscal 2025 EPS expected to drop by 9.2% to $30, followed by an 8.6% decline in fiscal 2026 to $27.41 [3] Stock Performance - Elevance Health shares have decreased by 6% over the past year, contrasting with a 16% increase in the S&P 500 Index and a 20.1% rise in the SPDR S&P Health Care Services ETF [4]